Which has higher valuation and earnings, MNPR or TRVI?

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Monopar Therapeutics N/A N/A -$13.72M -$1.90 N/A Trevi Therapeutics N/A N/A -$42.76M -$0.32 N/A

Is MNPR or TRVI more profitable?

Monopar Therapeutics' return on equity of -12.84% beat Trevi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Monopar Therapeutics N/A -12.84% -12.57% Trevi Therapeutics N/A -24.53% -23.37%

Does the media refer more to MNPR or TRVI?

In the previous week, Trevi Therapeutics had 5 more articles in the media than Monopar Therapeutics. MarketBeat recorded 11 mentions for Trevi Therapeutics and 6 mentions for Monopar Therapeutics. Trevi Therapeutics' average media sentiment score of 0.75 beat Monopar Therapeutics' score of 0.68 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trevi Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MNPR or NTLA?

In the previous week, Monopar Therapeutics had 3 more articles in the media than Intellia Therapeutics. MarketBeat recorded 6 mentions for Monopar Therapeutics and 3 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.86 beat Monopar Therapeutics' score of 0.68 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NRIX or MNPR?

In the previous week, Nurix Therapeutics had 2 more articles in the media than Monopar Therapeutics. MarketBeat recorded 8 mentions for Nurix Therapeutics and 6 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.68 beat Nurix Therapeutics' score of 0.59 indicating that Monopar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monopar Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, MNPR or BHVN?

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Monopar Therapeutics N/A N/A -$13.72M -$1.90 N/A Biohaven N/A N/A -$738.82M -$5.67 N/A

Is MNPR or BHVN more profitable?

Monopar Therapeutics' return on equity of -12.84% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Monopar Therapeutics N/A -12.84% -12.57% Biohaven N/A -866.46% -137.99%

Does the media prefer MNPR or BHVN?

In the previous week, Monopar Therapeutics had 4 more articles in the media than Biohaven. MarketBeat recorded 6 mentions for Monopar Therapeutics and 2 mentions for Biohaven. Monopar Therapeutics' average media sentiment score of 0.68 beat Biohaven's score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ABCL or MNPR?

In the previous week, Monopar Therapeutics had 4 more articles in the media than AbCellera Biologics. MarketBeat recorded 6 mentions for Monopar Therapeutics and 2 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.34 beat Monopar Therapeutics' score of 0.68 indicating that AbCellera Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monopar Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Monopar Therapeutics (MNPR) Competitors

$108.42 -2.71 (-2.43%)

As of 01:51 PM Eastern

Compare

MNPR vs. TRVI, NTLA, NRIX, BHVN, and ABCL

Should you buy Monopar Therapeutics stock or one of its competitors? MarketBeat compares Monopar Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Monopar Therapeutics include Trevi Therapeutics (TRVI), Intellia Therapeutics (NTLA), Nurix Therapeutics (NRIX), Biohaven (BHVN), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry.

How does Monopar Therapeutics compare to Trevi Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Trevi Therapeutics (NASDAQ:TRVI) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

In the previous week, Trevi Therapeutics had 5 more articles in the media than Monopar Therapeutics. MarketBeat recorded 11 mentions for Trevi Therapeutics and 6 mentions for Monopar Therapeutics. Trevi Therapeutics' average media sentiment score of 0.75 beat Monopar Therapeutics' score of 0.68 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trevi Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 9.7% of Monopar Therapeutics shares are held by company insiders. Comparatively, 18.3% of Trevi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Monopar Therapeutics' return on equity of -12.84% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-12.84%	-12.57%
Trevi Therapeutics	N/A	-24.53%	-23.37%

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A

Monopar Therapeutics presently has a consensus target price of $108.75, indicating a potential upside of 0.31%. Trevi Therapeutics has a consensus target price of $23.80, indicating a potential upside of 35.79%. Given Trevi Therapeutics' higher probable upside, analysts clearly believe Trevi Therapeutics is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Monopar Therapeutics has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.

Summary

Monopar Therapeutics and Trevi Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Monopar Therapeutics compare to Intellia Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

Monopar Therapeutics presently has a consensus target price of $108.75, indicating a potential upside of 0.31%. Intellia Therapeutics has a consensus target price of $20.19, indicating a potential upside of 80.39%. Given Intellia Therapeutics' higher possible upside, analysts plainly believe Intellia Therapeutics is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
Intellia Therapeutics	4 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.30

In the previous week, Monopar Therapeutics had 3 more articles in the media than Intellia Therapeutics. MarketBeat recorded 6 mentions for Monopar Therapeutics and 3 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.86 beat Monopar Therapeutics' score of 0.68 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intellia Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 9.7% of Monopar Therapeutics shares are owned by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Monopar Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

Monopar Therapeutics has higher earnings, but lower revenue than Intellia Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A
Intellia Therapeutics	$67.67M	23.11	-$412.69M	-$3.54	N/A

Monopar Therapeutics has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -597.04%. Monopar Therapeutics' return on equity of -12.84% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-12.84%	-12.57%
Intellia Therapeutics	-597.04%	-57.47%	-46.24%

Summary

Monopar Therapeutics beats Intellia Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Monopar Therapeutics compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Monopar Therapeutics (NASDAQ:MNPR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Nurix Therapeutics currently has a consensus target price of $34.08, indicating a potential upside of 48.65%. Monopar Therapeutics has a consensus target price of $108.75, indicating a potential upside of 0.31%. Given Nurix Therapeutics' higher probable upside, equities analysts plainly believe Nurix Therapeutics is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

Nurix Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market.

1.8% of Monopar Therapeutics shares are held by institutional investors. 6.7% of Nurix Therapeutics shares are held by company insiders. Comparatively, 9.7% of Monopar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Monopar Therapeutics has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Monopar Therapeutics' return on equity of -12.84% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Monopar Therapeutics	N/A	-12.84%	-12.57%

Monopar Therapeutics has lower revenue, but higher earnings than Nurix Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	28.33	-$264.46M	-$3.45	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

In the previous week, Nurix Therapeutics had 2 more articles in the media than Monopar Therapeutics. MarketBeat recorded 8 mentions for Nurix Therapeutics and 6 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.68 beat Nurix Therapeutics' score of 0.59 indicating that Monopar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monopar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Monopar Therapeutics beats Nurix Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Monopar Therapeutics compare to Biohaven?

Monopar Therapeutics (NASDAQ:MNPR) and Biohaven (NYSE:BHVN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

Monopar Therapeutics has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, Biohaven has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market.

Monopar Therapeutics currently has a consensus price target of $108.75, indicating a potential upside of 0.31%. Biohaven has a consensus price target of $21.63, indicating a potential upside of 44.55%. Given Biohaven's higher possible upside, analysts clearly believe Biohaven is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
Biohaven	2 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.67

Monopar Therapeutics' return on equity of -12.84% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-12.84%	-12.57%
Biohaven	N/A	-866.46%	-137.99%

1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 9.7% of Monopar Therapeutics shares are held by insiders. Comparatively, 13.8% of Biohaven shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Monopar Therapeutics had 4 more articles in the media than Biohaven. MarketBeat recorded 6 mentions for Monopar Therapeutics and 2 mentions for Biohaven. Monopar Therapeutics' average media sentiment score of 0.68 beat Biohaven's score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biohaven	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A

Summary

Monopar Therapeutics beats Biohaven on 9 of the 13 factors compared between the two stocks.

How does Monopar Therapeutics compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by insiders. Comparatively, 9.7% of Monopar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

AbCellera Biologics presently has a consensus target price of $8.00, suggesting a potential upside of 34.27%. Monopar Therapeutics has a consensus target price of $108.75, suggesting a potential upside of 0.31%. Given AbCellera Biologics' higher possible upside, research analysts plainly believe AbCellera Biologics is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

In the previous week, Monopar Therapeutics had 4 more articles in the media than AbCellera Biologics. MarketBeat recorded 6 mentions for Monopar Therapeutics and 2 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.34 beat Monopar Therapeutics' score of 0.68 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monopar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Monopar Therapeutics has a net margin of 0.00% compared to AbCellera Biologics' net margin of -181.75%. Monopar Therapeutics' return on equity of -12.84% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-181.75%	-14.86%	-10.62%
Monopar Therapeutics	N/A	-12.84%	-12.57%

Monopar Therapeutics has lower revenue, but higher earnings than AbCellera Biologics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	24.22	-$146.41M	-$0.48	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

AbCellera Biologics has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

Summary

AbCellera Biologics and Monopar Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Monopar Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MNPR vs. The Competition

Export

Metric	Monopar Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$725.61M	$3.66B	$6.82B	$12.36B
Dividend Yield	N/A	2.17%	2.67%	9.36%
P/E Ratio	-57.00	20.89	27.16	24.05
Price / Sales	N/A	302.10	573.09	112.68
Price / Cash	N/A	60.31	29.05	48.09
Price / Book	5.26	8.00	10.68	6.18
Net Income	-$13.72M	$23.81M	$3.59B	$331.63M
7 Day Performance	4.92%	-2.00%	-1.56%	-1.49%
1 Month Performance	60.13%	1.94%	1.10%	-1.21%
1 Year Performance	133.25%	43.60%	24.47%	17.67%

Monopar Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MNPR Monopar Therapeutics	1.3456 of 5 stars	$108.42 -2.4%	$108.75 +0.3%	+139.1%	$725.61M	N/A	N/A	10	News Coverage
TRVI Trevi Therapeutics	3.3284 of 5 stars	$19.50 +8.6%	$22.67 +16.2%	+178.0%	$2.55B	N/A	N/A	20	News Coverage Analyst Forecast High Trading Volume
NTLA Intellia Therapeutics	3.3164 of 5 stars	$17.43 -2.3%	$20.46 +17.4%	-5.6%	$2.49B	$67.67M	N/A	600
NRIX Nurix Therapeutics	3.6138 of 5 stars	$24.40 +1.5%	$32.20 +32.0%	+106.2%	$2.49B	$83.98M	N/A	300
BHVN Biohaven	2.9632 of 5 stars	$15.59 -2.8%	$21.63 +38.7%	+10.1%	$2.42B	N/A	N/A	239

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MNPR) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Monopar Therapeutics (MNPR) Competitors

MNPR vs. TRVI, NTLA, NRIX, BHVN, and ABCL

How does Monopar Therapeutics compare to Trevi Therapeutics?

Summary

How does Monopar Therapeutics compare to Intellia Therapeutics?

Summary

How does Monopar Therapeutics compare to Nurix Therapeutics?

Summary

How does Monopar Therapeutics compare to Biohaven?

Summary

How does Monopar Therapeutics compare to AbCellera Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNPR vs. The Competition

Monopar Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Monopar Therapeutics (MNPR) Competitors

MNPR vs. TRVI, NTLA, NRIX, BHVN, and ABCL

How does Monopar Therapeutics compare to Trevi Therapeutics?

Does the media refer more to MNPR or TRVI?

Do institutionals and insiders have more ownership in MNPR or TRVI?

Is MNPR or TRVI more profitable?

Which has higher valuation and earnings, MNPR or TRVI?

Do analysts rate MNPR or TRVI?

Which has more risk & volatility, MNPR or TRVI?

Summary

How does Monopar Therapeutics compare to Intellia Therapeutics?

Do analysts recommend MNPR or NTLA?

Does the media refer more to MNPR or NTLA?

Do institutionals and insiders believe in MNPR or NTLA?

Which has more volatility and risk, MNPR or NTLA?

Which has higher earnings & valuation, MNPR or NTLA?

Is MNPR or NTLA more profitable?

Summary

How does Monopar Therapeutics compare to Nurix Therapeutics?

Do analysts rate NRIX or MNPR?

Which has more risk & volatility, NRIX or MNPR?

Do insiders & institutionals have more ownership in NRIX or MNPR?

Is NRIX or MNPR more profitable?

Which has better valuation & earnings, NRIX or MNPR?

Does the media prefer NRIX or MNPR?

Summary

How does Monopar Therapeutics compare to Biohaven?

Which has more volatility and risk, MNPR or BHVN?

Do analysts recommend MNPR or BHVN?

Is MNPR or BHVN more profitable?

Do institutionals and insiders believe in MNPR or BHVN?

Does the media prefer MNPR or BHVN?

Which has stronger valuation & earnings, MNPR or BHVN?

Summary

How does Monopar Therapeutics compare to AbCellera Biologics?

Do insiders & institutionals have more ownership in ABCL or MNPR?

Do analysts prefer ABCL or MNPR?

Does the media prefer ABCL or MNPR?

Is ABCL or MNPR more profitable?

Which has preferable earnings & valuation, ABCL or MNPR?

Which has more risk and volatility, ABCL or MNPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNPR vs. The Competition

Monopar Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools